TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03482947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasonography-guided TAP block
Description: (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal epidural block
Description: (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
Study: NCT02379793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel, vehicle, liquid paraffin
Description: Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
Study: NCT00698555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study: NCT03420898

Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.

Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.

Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.

Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.

Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.

Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
Study: NCT02828150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure \[Harris-Benedict\] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI \>30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
Study: NCT04414631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat alfa
Description: Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
Study: NCT04571697

Intervention type: DRUG
Intervention: Methotrexate
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.

Intervention type: DRUG
Intervention: Anti-TNF
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
Study: NCT01482429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weaning-ventilator protocol
Description: We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
Study: NCT02759796

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tailoring the flap according to clinical assessment
Description: After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailoring the flap according to ICG Angiography assessment
Description: After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
Study: NCT02650466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanopulse System
Description: The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
Study: NCT03492710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Description: Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
Study: NCT01702870

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Study: NCT04510025

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
Study: NCT03682198

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS measurements on skin, skull and dura
Description: During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.

Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine's effect on brain oxygenation
Description: With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal vs. high inspired oxygen
Description: By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
Study: NCT03455777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKCEA-ANGPTL3-LRX
Description: Single open-label cohort
Study: NCT01515722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education intervention (HEI)
Description: * \<Part 1\> Understanding OAB~* \<Part 2\> Behavioral/lifestyle modification~* \<Part 3\> Bladder training~* \<Part 4\> Understanding antimuscarinics
Study: NCT03373955

Intervention type: DRUG
Intervention: pembrolizumab
Description: anti-programmed death 1 (PD-1) antibody
Study: NCT04548297

Intervention type: OTHER
Intervention: Assessment
Description: Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level

Intervention type: OTHER
Intervention: Assessment
Description: Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
Study: NCT01837797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1 mg
Description: once daily dose, tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 3 mg
Description: once daily dose, tablets, orally
Study: NCT04017897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)
Description: Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
Study: NCT00604188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone (SCH 000484)
Description: 2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone (SCH 000484)
Description: 2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subutex (SCH 028444)
Description: 2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
Study: NCT04956614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immobilisation duration
Description: immobilisation duration of 2,4,6 week after suture of Achilles tendon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immobilisation duration
Description: immobilisation duration of 2,4,6 week after suture of Achilles tendon
Study: NCT01503164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Pressure Therapy (PAP)
Description: Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: LifeStyle Counseling
Description: Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
Study: NCT01822145

Intervention type: DEVICE
Intervention: ICD
Study: NCT03588598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M
Description: a selective PI3Kδ inhibitor
Study: NCT01804998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sentinel Node Biopsy
Description: Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy Assisted Gastrectomy
Description: In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
Study: NCT01832662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: coffee, placebo enriched with polyphenols and placebo with caffeine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: coffee
Description: coffee, placebo enriched with polyphenols and placebo with caffeine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee polyphenols mixed with placebo
Description: coffee polyphenols mixed with placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: coffee polyphenols mixed with placebo
Description: coffee polyphenols mixed with placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltodextrin enriched with caffeine
Description: maltodextrin enriched with caffeine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin enriched with caffeine
Description: maltodextrin enriched with caffeine
Study: NCT04626986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast conserving surgery
Description: The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
Study: NCT01227928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800 mg daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo 800 mg daily for 24 months
Study: NCT01527162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAFO worn
Description: Child wears their prescribed SAFO for 14 days by random assignment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFO not worn
Description: Child does not wear their prescirbed SAFO for 14 days by random assignment
Study: NCT03094455

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental group
Description: Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
Study: NCT01745276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphosfonate
Description: External pins coated by biphosfonate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxylapatit
Description: External pins coated by Hydroxylapatit.
Study: NCT01155076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitality Product
Description: Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice a day for 8 weeks
Study: NCT03192969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid Treatment
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoid Treatment
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoid Treatment
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
Study: NCT02360800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spray Fibrin Sealant
Description: Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Hemostasis and chest Closure Routine
Description: Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
Study: NCT03269747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 2 tablets of Prednisone 20 Mg in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets in the morning
Study: NCT02634814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Exercise
Description: Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
Study: NCT01475032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (BDP)
Description: Beclomethasone (BDP) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (BDP) + Formoterol Fumarate (FF)
Description: free combo Beclomethasone (BDP) + FF for 12 weeks
Study: NCT02634814

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation
Description: Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day.
Study: NCT02101983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytosine Arabinoside
Study: NCT03561545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weightlessness (parabolic flight)
Description: weightlessness (parabolic flight)
Study: NCT04001738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct Transfer to Angio Suite
Description: Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
Study: NCT01215578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: sunitinib 37.5 mg/day (per os) for 6 months
Study: NCT04292639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vital Detect Pulse Oximeter
Description: The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
Study: NCT01957943

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SMOFLipid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SMOFLipid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: equivalent volume of 10% glucose solution
Description: Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
Study: NCT02803359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold